Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
19
Recruiting, industry sponsors, Hematology and blood cancers, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed194
19 trials
Showing 1 to 19, recently updated first.
OctapharmaIndustry
NCT05936580 · 28 participants (planned) · Start May 12, 2026 · Primary completion Feb 2027
Drug: Nuwiq · For: Hemophilia A
Sites: San Antonio, Texas; Helsinki, Finland; Chambray-lès-Tours, France · 17 sites in all
OctapharmaIndustry
NCT05935358 · 28 participants (planned) · Start Nov 28, 2023 · Primary completion Dec 2026
Drug: Nuwiq · For: Severe Hemophilia A
Sites: Dallas, Texas; Zagreb, Croatia; Helsinki, Finland · 18 sites in all
- Asciminib Roll-over StudyRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04877522 · 347 participants (planned) · Start Aug 30, 2022 · Primary completion Aug 30, 2030
Drug: Asciminib single agent; Imatinib and 4 more · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 88 sites in all
SanofiSanofi (SNY)
NCT06941870 · 35 participants (planned) · Start Sep 23, 2025 · Primary completion Oct 25, 2027
Drug: Efanesoctocog alfa · For: Factor VIII Deficiency
Sites: Los Angeles, California; Sacramento, California; Indianapolis, Indiana · 19 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07218341 · 150 participants (planned) · Start Mar 9, 2026 · Primary completion May 2030
Drug: Pirtobrutinib; Idelalisib · For: Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
Sites: Mobile, Alabama; Tucson, Arizona; Jacksonville, Florida · 50 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05201781 · 295 participants (planned) · Start Mar 9, 2022 · Primary completion Jul 29, 2037
Drug: Cilta-cel · For: Multiple Myeloma
Sites: Phoenix, Arizona; Duarte, California; San Francisco, California · 50 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07609940 · 30 participants (planned) · Start Jul 15, 2026 · Primary completion Oct 11, 2027
Drug: Linvoseltamab; Tocilizumab · For: Relapsed/Refractory Multiple Myeloma (RRMM)
Sites: Los Angeles, California; St. Petersburg, Florida; Baton Rouge, Louisiana · 7 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06651970 · 60 participants (planned) · Start Feb 4, 2025 · Primary completion Sep 30, 2032
Drug: Acalabrutinib · For: Chronic Lymphocytic Leukaemia; Moderate to Severe Cardiac Impairment
Sites: Charlotte, North Carolina; Columbus, Ohio; Philadelphia, Pennsylvania · 23 sites in all
SanofiSanofi (SNY)
NCT06145373 · 20 participants (planned) · Start Mar 1, 2024 · Primary completion May 28, 2028
Drug: Fitusiran (SAR439774); Clotting factor concentrates (CFC) or bypassing agents (BPA) and 2 more · For: Hemophilia A
Sites: Los Angeles, California; Flowood, Mississippi; Taipei, Taiwan
AbbVieAbbVie (ABBV)
NCT07044687 · 100 participants (planned) · Start Jul 24, 2025 · Primary completion Nov 2027
Drug: Venetoclax; Azacitidine and 1 more · For: Acute Myeloid Leukemia
Sites: Gurgaon, India; Bengaluru, India; Thiruvananthapuram, India · 14 sites in all
- Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient WomenPivotal-lookingRecruiting
Pharmanutra S.p.a.Industry
NCT07308769 · 146 participants (planned) · Start Dec 11, 2025 · Primary completion Oct 2026
Drug: Ferric Maltol (Feraccru®) · For: Anemia; Iron Deficiency Anemia (IDA)
Sites: Barcelona, Spain; Málaga, Spain; Sant Cugat del Vallès, Spain · 7 sites in all
Rigel PharmaceuticalsIndustry
NCT07486713 · 16 participants (planned) · Start Feb 23, 2026 · Primary completion Apr 30, 2027
Drug: Olutasidenib; CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates · For: AML (Acute Myeloid Leukemia); Glioma; Cholangiocarcinoma and 1 more
Sites: Orange, California; New York, New York
PfizerPfizer (PFE)
NCT06057402 · 80 participants (planned) · Start Oct 3, 2023 · Primary completion Feb 22, 2032
Drug: Elranatamab · For: Multiple Myeloma
Sites: Irvine, California; Orange, California; Fort Collins, Colorado · 33 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04657822 · 130 participants (planned) · Start Jun 10, 2021 · Primary completion Jun 10, 2031
Drug: Crizanlizumab · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Washington D.C., District of Columbia; Augusta, Georgia · 31 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07308574 · 20 participants (planned) · Start Dec 19, 2025 · Primary completion Jun 25, 2027
Drug: Ravulizumab · For: aHUS; Atypical Hemolytic Uremic Syndrome
Sites: Bunkyō City, Japan; Hirakata-shi, Japan; Iruma-Gun, Japan · 12 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06876649 · 787 participants (planned) · Start May 20, 2025 · Primary completion May 2030
Drug: Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
Sites: Jacksonville, Florida; Miami, Florida; Sarasota, Florida · 38 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06876662 · 279 participants (planned) · Start May 20, 2025 · Primary completion May 2030
Drug: Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma
Sites: Miami, Florida; Sarasota, Florida; Atlanta, Georgia · 36 sites in all
TakedaTakeda (TAK)
NCT06831370 · 124 participants (planned) · Start Aug 28, 2024 · Primary completion Mar 31, 2028
Drug: Brentuximab Vedotin; Doxorubicin and 2 more · For: Hodgkin Lymphoma
Sites: Vijayawada, India; Guwahati, India; Surat, India · 11 sites in all
Zydus Lifesciences LimitedIndustry
NCT05515367 · 1,004 participants (planned) · Start Apr 20, 2023 · Primary completion Jun 30, 2025
Drug: Desidustat · For: Chronic Kidney Diseases; Anemia of Chronic Kidney Disease
Sites: Sheikhpura, India
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.